Gordon Research Conferences
PI_Conferences PI_Conferences_Past
Conference Program
 
New Antibacterial Discovery & Development
Extending the Antibiotic Era
March 16-21, 2014
Four Points Sheraton / Holiday Inn Express
Ventura, CA

This Gordon Research Conference will bring together industry, academic and government leaders involved in the discovery and development of novel antibacterial agents. The discovery of antibiotics and their introduction into clinical practice in the 1940s fundamentally changed the practice of medicine. The increase and spread of antibiotic-resistant bacteria and the reduced investment in this space by the pharmaceutical industry have given rise to the specter of a return to the pre-antibiotic era. Ultimately, it is the goal of the scientific community, and certainly that of the attendees, to forestall that event and to prevent the serious consequences that would come inexorably from it.

Previous meetings have defined the challenges facing the field. These range from the innate ability of bacteria to defend themselves in the face of the challenge by antibiotics, to the regulatory hurdles to the approval of novel agents, to the economic forces reducing investment in this space. But they have also helped identify some of the possible solutions, including further investment in basic biology, increased academic-industry partnership, and ways to move outside traditional discovery and development pathways. The goal of the 2014 GRC will be to further the discussion of solutions, with an emphasis on going back to the basics, moving beyond the limitations of high-throughput-screening-driven target-based discovery, and looking to fields outside traditional antibiotic research for inspiration and solutions. The conference will bring together an international, multi-disciplinary group of researchers from industry, academics, government and foundations and will help lay the groundwork for the next generation of life-saving antibiotics.


Contributors

SUNDAY
4:00 pm - 8:00 pmArrival and Check-in (Office Closed 6:00 pm - 7:45 pm)
6:00 pmDinner
7:30 pm - 7:40 pmWelcome / Introductory Comments by GRC Site Staff
7:40 pm - 9:30 pmResistance and the Gram Positive Cell Wall
Discussion Leader: Jennifer Leeds (Novartis)
7:40 pm - 8:20 pmPatrice Courvalin (Institute Pasteur)
"Antibiotics Are Self-Destructive"
8:20 pm - 8:35 pmDiscussion
8:35 pm - 9:15 pmAlexander Tomasz (Rockefeller University)
"From Gene to Phenotype: New Genetic Determinants and Biochemical Mechanisms that Define the Antibiotic Resistant Phenotype in MRSA"
9:15 pm - 9:30 pmDiscussion
MONDAY
7:30 am - 8:30 amBreakfast
8:30 amGroup Photo
9:00 am - 12:30 pmPreclinical: Novel Approaches
Discussion Leader: Alex O'Neill (University of Leeds)
9:00 am - 9:30 amMarvin Miller (Notre Dame)
"Design, Syntheses and Studies of New Antibiotics and Selective Anti-TB agents"
9:30 am - 9:40 amDiscussion
9:40 am - 10:10 amVanessa Sperandio (UT Southwestern)
"QseC Small Molecule Inhibitors as an Anti-Virulence Strategy Against Gram-Negative Pathogens"
10:10 am - 10:20 amDiscussion
10:20 amCoffee Break
10:50 am - 11:20 amErin Carlson (Indiana University)
"Small Molecule Inhibitors of Histidine Kinase Activity"
11:20 am - 11:30 amDiscussion
11:30 am - 12:00 pmVincent Fischetti (Rockefeller University)
"Development of Epimerox, a Novel Compound with Reduced Resistance Potential to Treat Gram-Positive Bacterial Infections"
12:00 pm - 12:10 pmDiscussion
12:10 pm - 12:25 pmPoster Talk: Ruben Tommasi (AstraZeneca)
"Improving Our Understanding of Porin Permeability in Gram-Negative Bacteria"
12:25 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session
6:00 pmDinner
7:30 pm - 9:30 pmReactive Oxygen Species in Antibiotic Mechanism
Discussion Leader: Daniel Ritz (Actelion)
7:30 pm - 8:00 pmDan Dwyer (Boston University)
"Bactericidal Antibiotics, Metabolic Alterations and Reactive Oxygen Species"
8:00 pm - 8:10 pmDiscussion
8:10 pm - 8:40 pmKim Lewis (Northeastern University)
"Bactericidal and Sterilizing Antibiotics: How They Kill Regular and Dormant Cells"
8:40 pm - 8:50 pmDiscussion
8:50 pm - 9:20 pmGreg Somerville (University of Nebraska)
"Bacterial Cultivation and Antibiotic Susceptibility in Staphylococcus aureus"
9:20 pm - 9:30 pmDiscussion
TUESDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmPreclinical: Taking Aim at Resistance
Discussion Leader: Man-wah Tan (Genentech)
9:00 am - 9:30 amDeb Hung (Broad Institute)
"Killing More Bugs: Is This the Best That We Can Do?"
9:30 am - 9:40 amDiscussion
9:40 am - 10:10 amTerry Roemer (Merck)
"Chemical Genetic Strategies to Restoring MRSA Susceptibility to β-Lactam Antibiotics"
10:10 am - 10:20 amDiscussion
10:20 amCoffee Break
10:50 am - 11:20 amPaul Hergenrother (University of Illinois)
"Small Molecules that Specifically Kill Fluoroquinolone-Resistant Bacteria"
11:20 am - 11:30 amDiscussion
11:30 am - 12:00 pmChristian Melander (North Carolina State University)
"Small Molecule Suppression of Antibiotic Resistance by Targeting Bacterial Two Component Systems"
12:00 pm - 12:10 pmDiscussion
12:10 pm - 12:25 pmPoster Talk: Eleanor Allen (Stony Brook University)
"Translating Slow-Binding Inhibition Kinetics into Cellular and In Vivo Effects"
12:25 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session
6:00 pmDinner
7:30 pm - 9:30 pmMicrobiome - Opportunities and Challenges
Discussion Leader: Eric Pamer (Sloan-Kettering)
7:30 pm - 8:00 pmMichael Surette (McMaster University)
"The Challenge of Polymicrobial and Chronic Infections: Separating Friend from Foe"
8:00 pm - 8:10 pmDiscussion
8:10 pm - 8:40 pmHenry Haiser (Harvard University)
"Predicting and Manipulating Drug Inactivation by the Human Gut Microbiome"
8:40 pm - 8:50 pmDiscussion
8:50 pm - 9:20 pmLaura Cox (NYU)
"The Role of Early-Life Antibiotic Exposure in Shaping Adult Body Composition"
9:20 pm - 9:30 pmDiscussion
WEDNESDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmClinical Update: Experience with New Regulatory Pathways
Discussion Leader: Alita Miller (AstraZeneca)
9:00 am - 9:30 amNestor Molfino (KaloBios)
"Clinical Development of an Anti-Pseudomonas aeruginosa Type III Secretion System Antibody in Respiratory Diseases"
9:30 am - 9:40 amDiscussion
9:40 am - 10:10 amMary Celine Scott (Trius/Cubist)
"Clinical Development of Tedizolid Phosphate - Executing an ABSSSI/cSSTI Phase 3 Program in the Global Regulatory Landscape"
10:10 am - 10:20 amDiscussion
10:20 amCoffee Break
10:50 am - 11:20 amLynn Connolly (Achaogen)
"Clinical Development of Plazomicin, a Next-Generation Aminoglycoside, for Serious Infections Due to Multidrug Resistant Enterobacteriaceae"
11:20 am - 11:30 amDiscussion
11:30 am - 12:00 pmJohn O'Donnell (AstraZeneca)
"Avibactam Combinations in the Clinic"
12:00 pm - 12:10 pmDiscussion
12:10 pm - 12:25 pmPoster Talk: John Alumasa (Pennsylvania State University)
"Exploiting the Potential of Trans-Translation to Identify Molecular Targets for New Classes of Lead Antibiotic Candidates"
12:25 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session
6:00 pmDinner
7:00 pm - 7:30 pmBusiness Meeting
Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair
7:30 pm - 9:30 pmPublic-Private Partnerships to Advance Antibacterial Discovery
Discussion Leader: Nicole Mahoney (Pew Charitable Trusts)
7:30 pm - 8:00 pmAngela Wittelsberger (Innovative Medicines Initiative)
"Public-Private Partnership to Address the Threat of Antimicrobial Resistance: The Innovative Medicines Initiative's ND4BB Programme"
8:00 pm - 8:10 pmDiscussion
8:10 pm - 8:40 pmDebra Hanna (Critical Path Institute)
"Critical Path to TB Drug Regimens: A Successful Consortium Model for Innovation"
8:40 pm - 8:50 pmDiscussion
8:50 pm - 9:05 pmAnn Eakin (NIH)
"NIAID Preclinical and Clinical Resources to Facilitate Antibacterial Development"
9:05 pm - 9:10 pmDiscussion
9:10 pm - 9:25 pmPoster Talk: Danielle Demers (University of South Florida)
"An Epigenetics Based Fungal Metabolite Screening Program for Antibacterial Lead Compounds"
9:25 pm - 9:30 pmDiscussion
THURSDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmResistance: Mechanisms and Detection
Discussion Leader: Heike Brötz-Oesterhelt (University of Dusseldorf)
9:00 am - 9:30 amLori Burrows (McMaster University)
"Novel Phenotypes Revealed by 'Ineffective' Antibiotic Concentrations"
9:30 am - 9:40 amDiscussion
9:40 am - 10:10 amJuan Hermoso (Inst. Rocasolano. Spanish National Research Council)
"Structural Basis of Allosteric Mechanism Controlling Antibiotic Resistance in PBP2a from MRSA"
10:10 am - 10:20 amDiscussion
10:20 amCoffee Break
10:50 am - 11:20 amGautam Dantas (Washington University)
"Networks of Exchanging Antibiotic Resistance in Human-Associated and Environmental Bacteria"
11:20 am - 11:30 amDiscussion
11:30 am - 12:00 pmMichael Hodsdon (Yale University)
"Rapid Detection of Carbapenemase Activity in Clinical Specimens by Mass Spectrometry"
12:00 pm - 12:10 pmDiscussion
12:10 pm - 12:25 pmTBA (Late-Breaking Topic Talk)
12:25 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 6:00 pmPoster Session
6:00 pmDinner
7:30 pm - 9:30 pmResistance: Combinations to Fight Resistance
Discussion Leader: Arnold Bayer (UCLA School of Medicine)
7:30 pm - 8:00 pmAnn Kwong (InnovaTID)
"Lessons Learned from the Use of Combinations in HCV"
8:00 pm - 8:10 pmDiscussion
8:10 pm - 8:40 pmKhisi Mdluli (Global Alliance for TB Drug Development)
"Pre-Clinical and Clinical Development of Regimens that Shorten the Duration of TB Therapy and Eliminate Drug Resistance"
8:40 pm - 8:50 pmDiscussion
8:50 pm - 9:20 pmVictor Nizet (University of California, San Diego)
"Adjunctive Antibiotic Therapy to Enhance Endogenous and Administered Peptide Antibiotics: From Bedside to Bench"
9:20 pm - 9:30 pmDiscussion
FRIDAY
7:30 am - 8:30 amBreakfast
9:00 amDeparture

Funding for this conference was made possible [in part] by 1 R13 AI111916-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

 
© 2014 Gordon Research Conferences Search | Contact | Terms of Use | Privacy Policy | Follow us: Facebook Twitter